Contraceptive Technology Update – October 1, 2020
October 1, 2020
View Issues
-
New Male Contraceptives May Be on the Horizon
Researchers across the world are studying hormonal and nonhormonal male contraceptive products in hopes of being the first to bring a new, reversible contraceptive for men to market within the next 10 to 20 years.
-
New Male Contraceptive Options in the Pipeline
There is a wide variety of potential male contraceptive products in the research pipeline. Hormonal contraceptive products have been studied a long time, but nonhormonal products also are under study.
-
Fledgling Research Holds Promise for Safe, On-Demand Male Contraceptive Pill
Researchers have found a possible way to target soluble adenylyl cyclase (sAC:ADY10), which is essential for male fertility.
-
Marketing a Male Contraceptive Plays Role in Availability
The marathon race for finding an effective and safe male contraceptive has reached a hurdle that was not as much of a barrier for the research race to bring the first female contraceptive to market: Someone needs to prove men want their own contraceptive and will use whatever method succeeds.
-
Study: Women Use Female Condoms More When Their Partners Approve
Female (internal) condoms were hailed as a method that gave women control over their disease protection. But one factor was overlooked: Women’s reproductive health decisions are influenced by male partners.
-
Why Has the Female Condom Not Been Widely Adopted in the United States?
Contraceptive Technology Update asked two researchers involved in a new study about female (internal) condom use to answer some questions about the use of this contraceptive method in the United States.
-
Etonogestrel Contraceptive Implant and VTE in Postpartum Women
In this national retrospective cohort study of postpartum women, use of the etonogestrel contraceptive implant immediately
postpartum was not associated with an increased rate of readmission for venous thromboembolism within 30 days of delivery.